This paper develops viroVbot, an in vivo CAR-T platform with reduced immunogenicity and safety, showing efficacy in treating multiple myeloma and gastric cancer through sequential redosing.

bioRxiv · Jul 2, 2026 · PreprintBioengineering

Reprogramming BCMA-Targeted CAR-T Cells through γ-Secretase Modulation Blocks Antigen Shedding and Extends CAR-T Longevity

Sheetal Sharma Sheetal, Varnit Chauhan, Zahoor Ahmad Bhat, Jyotirmoi Aich, Divya, Sunita Gupta, Divya Rashmi Singh, Raquib Alam, Drashti Dave, Preet Patel, Nisha Chaudhary, Deepak Kumar Singh, Vijay Pal Singh, Mohammad Husain, Amit Kumar Srivastava, , Tanveer Ahmad

This paper develops SHEDLOCK CAR-T cells that block BCMA shedding, enhancing their cytotoxicity and longevity in multiple myeloma models.

bioRxiv · Jan 23, 2026 · PreprintImmunology

AI-Guided CAR Designs and AKT3 Degradation Synergize to Enhance Bispecific and Trispecific CAR-T Cell Persistence and Overcome Antigen Escape

Md Sufyan Ansari, Varnit Chauhan, Aashi Singh, Areej Akhtar, Nisha Chaudhary, Reegina Tyagi, Divya, Kashif Husain, Sheetal Sharma, Raquib Alam, Md Shakir, Mehak Pracha, Samreen Anjum, Mohd Nadeem, Md Imam Faizan, , Tanveer Ahmad

This study designs and evaluates AI-optimized CAR-T cells with AKT3 degradation to improve persistence and overcome antigen escape in cancer therapy.

bioRxiv · Jun 12, 2025 · PreprintCancer Biology